Results 111 to 120 of about 1,772,527 (156)
Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial
Cancer, Volume 132, Issue 21, 1 November 2026.Abstract Background
Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.Arnaud Pigneux, Pierre‐Yves Dumas, Marc Bernard, Norbert Vey, Audrey Bidet, Ariane Mineur, Aline Schmidt, Martin Carré, Mario Ojeda, Sarah Bertoli, Anne Banos, Pierre Peterlin, Romain Guièze, Yohan Desbrosses, Gabrielle Roth Guepin, Célestine Simand, Thibaut Leguay, Emmanuel Gyan, Eric Jourdan, Jean‐Philippe Vial, Tony Marchand, Yosr Hicheri, Marie C. Béné, Jean Francois Hamel, Christian Récher +24 morewiley +1 more sourceModulation of the RNA‐sensing RIG/MAVS pathway bypasses resistance to hypomethylating agents in acute myeloid leukemia
HemaSphere, Volume 10, Issue 11, November 2026.Abstract
DNA hypomethylating agents (HMAs) such as 5‐azacytidine (5‐AZA) are a cornerstone in the treatment of acute myeloid leukemia (AML), but development of resistance represents a major clinical challenge. Apart from epigenetic reprogramming of malignant cell clones, therapy with HMA is increasingly recognized to facilitate antineoplastic immunity, Nadia El Khawanky, Tatiana Nedelko, Giada Mandracci, Yunus Barth, Yuan Jiang, Kai Wang, Marc Rosenbaum, Christin Weiß, Christoph Geisenberger, Stefan Enßle, Ana M. Gómez Martínez, Sascha Göttert, Noomen Hamed, Julius C. Fischer, Jürgen Ruland, Dirk H. Busch, Hendrik Poeck, Katharina S. Götze, Anna L. Illert, Florian Bassermann, Simon M. Heidegger +20 morewiley +1 more sourceVenetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study
Blood and Lymphatic Cancer: Targets and TherapyNa Zhao,1,2,* Lijun Zhu,1,* Xing Hu,1,* Juan Tong,1 Hongfeng Ge,3 Li Ye,4 Xijun Zhu,5 Can Gai,6 Yuhu Feng,7 Lei Zhang,1 Li Wang,1 Guangyu Sun,1 Lei Xue,1 Xiaoyu Zhu,1 Changcheng Zheng1,8 1Department of Hematology, the First ...Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, Zhu X, Gai C, Feng Y, Zhang L, Wang L, Sun G, Xue L, Zhu X, Zheng C +14 moredoaj Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
Hematological Oncology, Volume 44, Issue 6, November 2026.ABSTRACT
In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla +9 morewiley +1 more sourceTargeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 11, November 2026.Overcoming chemoresistance in gastric cancer by targeting TLR2. ABSTRACT
Chemoresistance remains a major barrier to effective treatment of gastric cancer (GC), particularly in advanced disease, where cytotoxic chemotherapy often yields limited and transient responses.Kuanheng Zheng, Xinjian Lei, Bin Lin, Qianhong Yang, Cong He, Jin Gao, Feng Li +6 morewiley +1 more sourceOlutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML
European Journal of Haematology, Volume 117, Issue 6, Page 1671-1675, December 2026.Shira N. Dinner, Justin M. Watts, Jorge E. Cortes, Jay Yang, Maria R. Baer, Gail J. Roboz, Karen W. L. Yee, Antonio Curti, David C. Taussig, Jürgen Krauter, Thomas Prebet, Hua Tian, Aaron D. Sheppard, Pierre Peterlin, Carolyn Grove, Christian Récher, Stéphane de Botton +16 morewiley +1 more sourceDistinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients
British Journal of Haematology, Volume 209, Issue 5, Page 2148-2159, November 2026.Summary
Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...Hyunkyung Park, Eun‐Ji Choi, Young‐Uk Cho, Yunsuk Choi, Han‐Seung Park, Jung‐Hee Lee, Joon Young Hur, Jisu Jeong, Seungah Cha, Yueun Lee, Young‐Shin Lee, Young‐Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je‐Hwan Lee +15 morewiley +1 more sourceComparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium
British Journal of Haematology, Volume 209, Issue 5, Page 2160-2167, November 2026.Summary
Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Estelle Borgne, Anne‐Charlotte de Grande, Audrey Sarry, Ziyad Acheaibi, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Marie‐Anne Hospital, Martin Carré, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz +22 morewiley +1 more source